Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LVR012
MIFTS: 68

Liver Cirrhosis

Categories: Endocrine diseases, Gastrointestinal diseases, Liver diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Cirrhosis

About this section

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 38 12 76 55 44 15 73
Cirrhosis 12 75 29 55 43 40 73
Cirrhosis, Cryptogenic 73
Cryptogenic Cirrhosis 75
Cirrhosis of Liver 12
Cirrh 75

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases Gastrointestinal diseases Liver diseases
See all MalaCards categories (disease lists)


Sources

Summaries for Liver Cirrhosis

About this section
MedlinePlus : 43 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and hepatitis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Cirrhosis is HULC (Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA
LncRNA HULC affects the differentiation of Treg in HBV-related liver cirrhosis.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are HIF-1 signaling pathway and Lung fibrosis. The drugs Adefovir Dipivoxil and Telbivudine have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood.

Wikipedia : 76 Cirrhosis is a condition in which the liver does not function properly due to long-term damage. This... more...

Sources

Related Diseases for Liver Cirrhosis

About this section

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 380)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 34.3 AFP ALB CYP2E1 F2 SLC17A5 TF
2 hepatitis 32.2 AFP F2 GPT SLC17A5
3 hypersplenism 32.0 ALB F2 SERPINC1
4 portal hypertension 32.0 ALB EDN1 F2 GPT
5 portal vein thrombosis 31.9 AFP F2 SERPINC1
6 hepatic encephalopathy 31.8 ALB F2 GPT SLC17A5
7 hepatitis b 31.8 AFP ALB F2 GPT SLC17A5
8 esophageal varix 31.6 AFP ALB F2 SERPINC1
9 hepatic coma 31.6 ALB F2 GPT
10 hemosiderosis 31.5 GPT HFE TF
11 protein-energy malnutrition 31.4 ALB GPT TF
12 hepatorenal syndrome 31.3 ALB EDN1 F2 NPPA REN
13 antipyrine metabolism 31.2 ALB F2
14 cholangitis 31.2 ALB F2 GPT
15 hypoaldosteronism 31.2 NPPA REN
16 choledocholithiasis 31.1 ALB F2 GPT SLC17A5
17 abdominal tuberculosis 31.1 ALB F2
18 dysfibrinogenemia 31.0 ALB F2 SERPINC1
19 alcohol abuse 31.0 CYP2E1 GPT SLC17A5 TF
20 nonalcoholic steatohepatitis 30.9 F2 GPT HFE SLC17A5
21 acute kidney tubular necrosis 30.9 ALB HGF NPPA
22 siderosis 30.8 HFE SERPINA1 TF
23 pulmonary embolism 30.8 ALB F2 SERPINC1
24 alpha-1-antitrypsin deficiency 30.8 ALB HFE SERPINA1 SERPINC1
25 biliary atresia 30.8 ALB GPT HGF
26 alcoholic hepatitis 30.8 ALB CYP2E1 F2 GPT SLC17A5
27 acute liver failure 30.5 ALB F2 GPT HGF SLC17A5
28 constrictive pericarditis 30.5 ALB SERPINA1
29 wilson disease 30.5 ALB F2 GPT HFE TF
30 chronic kidney failure 30.4 ALB EDN1 NPPA REN TF
31 viral hepatitis 30.4 AFP ALB F2 GPT HFE SERPINA1
32 kidney disease 30.3 ALB EDN1 NPPA REN TF
33 hemochromatosis, type 1 30.2 HFE SERPINA1 TF
34 obstructive jaundice 30.1 ALB EDN1 F2 GPT HGF REN
35 myocardial infarction 30.1 ALB EDN1 F2 NPPA REN SERPINC1
36 hepatitis a 30.0 AFP ALB F2 GPT SERPINA1 SERPINC1
37 congestive heart failure 29.9 EDN1 HOTAIR NPPA REN
38 fatty liver disease 29.8 CYP2E1 GPT HFE MALAT1 SLC17A5
39 hypertension, essential 29.7 ALB EDN1 GAS5 NPPA REN
40 pulmonary hypertension 29.6 EDN1 MALAT1 NPPA REN SERPINC1
41 diabetes mellitus, noninsulin-dependent 29.5 ALB EDN1 GAS5 GPT SLC17A5
42 liver disease 28.9 AFP ALB CYP2E1 F2 GPT HFE
43 cholangiocarcinoma 28.9 AFP ALB HGF HULC MALAT1
44 diabetes mellitus 28.8 ALB EDN1 HFE MALAT1 MEG3 REN
45 hepatocellular carcinoma 27.2 AFP ALB F2 GAS5 HGF HOTAIR
46 myeloma, multiple 26.8 ALB GAS5 HGF HOTAIR MALAT1 MEG3
47 esophageal cancer 26.7 ALB GAS5 HOTAIR HULC MALAT1 MEG3
48 gastric cancer 26.5 GAS5 HGF HOTAIR HULC MALAT1 MEG3
49 primary biliary cirrhosis 11.8
50 non-a-e hepatitis 11.2 ALB F2

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis
Sources

Symptoms & Phenotypes for Liver Cirrhosis

About this section

UMLS symptoms related to Liver Cirrhosis:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, gastrointestinal gas
Sources

Drugs & Therapeutics for Liver Cirrhosis

About this section

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 723)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
2
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2 3424-98-4 159269
3
Entecavir Approved, Investigational Phase 4,Phase 1,Phase 2,Not Applicable 142217-69-4 153941
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
5
Losartan Approved Phase 4,Phase 3 114798-26-4 3961
6
Magnesium oxide Approved Phase 4 1309-48-4 14792
7
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
8
Azithromycin Approved Phase 4 83905-01-5 55185 447043
9
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
10
Cefoxitin Approved Phase 4 35607-66-0 441199
11
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Early Phase 1,Not Applicable 85721-33-1 2764
12
Imipenem Approved Phase 4,Not Applicable 74431-23-5, 64221-86-9 104838
13
Vancomycin Approved Phase 4 1404-90-6 441141 14969
14
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
15
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 143491-57-0 60877
16
Metformin Approved Phase 4,Phase 2,Phase 3,Not Applicable 657-24-9 14219 4091
17
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
18
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
19
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
20
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
21
Carvedilol Approved, Investigational Phase 4,Phase 3,Not Applicable 72956-09-3 2585
22
Nadolol Approved Phase 4,Phase 3,Not Applicable 42200-33-9 39147
23
Insulin Glargine Approved Phase 4 160337-95-1
24
Insulin glulisine Approved Phase 4 207748-29-6
25
Zinc Approved, Investigational Phase 4,Not Applicable 7440-66-6 23994
26
Lactulose Approved Phase 4,Phase 2,Phase 3,Not Applicable 4618-18-2 11333
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
28 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9041-08-1
29
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
31
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 59467-70-8 4192
32
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 2078-54-8 4943
33
Tolvaptan Approved Phase 4,Phase 2,Phase 3,Phase 1 150683-30-0 216237
34
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
35
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
36
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
37
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
38
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1 10102-43-9 145068 160954
39
Prazosin Approved Phase 4,Phase 2 19216-56-9 4893
40
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
41
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
42
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
43
Carboplatin Approved Phase 4,Phase 2,Phase 3 41575-94-4 10339178 498142 38904
44
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
45
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 284461-73-0 216239 406563
46
Terlipressin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 14636-12-5 72081
47
Bisacodyl Approved Phase 4 603-50-9
48
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
49
Liraglutide Approved Phase 4 204656-20-2 44147092
50
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401

Interventional clinical trials:

(show top 50) (show all 1856)
# Name Status NCT ID Phase Drugs
1 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
2 Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB) Unknown status NCT01380951 Phase 4 telbivudine
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
5 Prevention of Decompensation in Liver Cirrhosis Unknown status NCT00239096 Phase 4 losartan (drug)
6 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
7 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
8 Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
9 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
10 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
11 Metformin Experience on Minimal Hepatic Encephalopathy Unknown status NCT02470546 Phase 4 Metformin;Placebo
12 Study About Simvastatin in Portal Hypertension in Compensated Cirrhosis Unknown status NCT01282398 Phase 4 Simvastatin;placebo
13 A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
14 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
15 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
16 Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis Unknown status NCT00332904 Phase 4 propranolol;spironolactone
17 Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
18 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
19 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
20 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
21 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
22 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
23 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
24 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
25 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
26 The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
27 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
28 Primary Prevention of Gastric Variceal Bleeding : Endoscopic Treatment Versus Non-selective Beta-blocker Unknown status NCT01298271 Phase 4 propranolol
29 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
30 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
31 Propofol and Fentanyl Versus Midazolam and Fentanyl for Endoscopy Sedation in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
32 Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
33 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
34 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
35 Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response Unknown status NCT00563602 Phase 4
36 Transfusion Requirements in Gastrointestinal (GI) Bleeding Unknown status NCT00414713 Phase 4
37 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
38 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
39 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
40 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
41 EFFORT Further Extension Study Unknown status NCT02826070 Phase 4 Telbivudine;Adefovir dipivoxil
42 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
43 The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure Unknown status NCT02489864 Phase 4 Terlipressin
44 Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Unknown status NCT00575627 Phase 4 Peg-Interferon alpha2a plus Ribavirin
45 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
46 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
47 Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients Unknown status NCT01853709 Phase 4 Polyethylene glycol (PEG);Bisacodyl
48 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
49 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
50 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 21771778 22121493
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Sources

Genetic Tests for Liver Cirrhosis

About this section

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis 29
Sources

Anatomical Context for Liver Cirrhosis

About this section

MalaCards organs/tissues related to Liver Cirrhosis:

41
Liver, Bone, Testes, Kidney, Bone Marrow, Endothelial, Spleen
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Liver Cirrhosis

About this section

Articles related to Liver Cirrhosis:

(show top 50) (show all 1751)
# Title Authors Year
1
Dietary Interventions in Liver Cirrhosis. ( 29912757 )
2018
2
The Impact of Outpatient Clinical Care on the Survival and Hospitalisation Rate in Patients with Alcoholic Liver Cirrhosis. ( 29520208 )
2018
3
Diagnostic and Prognostic Role of Serum Interleukin-6 in Malignant Transformation of Liver Cirrhosis. ( 29963457 )
2018
4
Anticoagulation for Portal Vein Thrombosis in Liver Cirrhosis: Not Only Recanalize the PortalA Vein. ( 29351835 )
2018
5
Circulating Endothelial Progenitor Cells Present an Inflammatory Phenotype and Function in Patients With Alcoholic Liver Cirrhosis. ( 29872403 )
2018
6
Managing portal hypertension in patients with liver cirrhosis. ( 29780579 )
2018
7
The protective effect of pentoxifylline versus silymarin on the pancreas through increasing adenosine by CD39 in a rat model of liver cirrhosis: Pharmacological, biochemical and histological study. ( 29408309 )
2018
8
Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. ( 29971486 )
2018
9
Doppler assessment of children with liver cirrhosis and portal hypertension in comparison with a healthy control group: An analytical cross-sectional study. ( 29937902 )
2018
10
Changing Etiology in Liver Cirrhosis in Sapporo, Japan. ( 29963470 )
2018
11
Platelet Count and Prediction of Bleeding in Patients With Liver Cirrhosis. ( 29895981 )
2018
12
Importance of the Average Glucose Level and Estimated Glycated Hemoglobin in a Diabetic Patient with Hereditary Hemolytic Anemia and Liver Cirrhosis. ( 29225250 )
2018
13
Number of hospital contacts with alcohol problems predicts later risk of alcoholic liver cirrhosis. ( 29528775 )
2018
14
Severe hyponatremia after direct-acting antiviral treatment in a patient with virus C compensated liver cirrhosis and kidney transplant. ( 29922767 )
2018
15
Leukemic mature B-cell neoplasm observed during the treatment with romiplostim in patient with thrombocytopenia and liver cirrhosis. ( 29881570 )
2018
16
Refractory Ascites in Liver Cirrhosis. ( 29973706 )
2018
17
Effect of sirolimus on liver cirrhosis and hepatic encephalopathy of common bile duct-ligated rats. ( 29444470 )
2018
18
Evaluation of Hepatoprotective Effect of Curcumin on Liver Cirrhosis Using a Combination of Biochemical Analysis and Magnetic Resonance-Based Electrical Conductivity Imaging. ( 29887757 )
2018
19
Molecular quantification and differentiation of Candida species in biological specimens of patients with liver cirrhosis. ( 29897895 )
2018
20
VALIDATION OF CLIF-C-ACLF SCORE FOR ALCOHOLIC LIVER CIRRHOSIS. ( 29905553 )
2018
21
Use of indocyanine green dye clearance in a patient with liver cirrhosis undergoing hepatectomy: a clinical image. ( 29950373 )
2018
22
Estimation of hepatic fat fraction using modified Dixon magnetic resonance imaging techniques: effect of liver cirrhosis. ( 29448119 )
2018
23
Efficacy and safety of endoscopic submucosal dissection for gastric neoplasms in patients with compensated liver cirrhosis: a propensity score-matched case-control study. ( 29410022 )
2018
24
Genetic polymorphisms in ataxin-3 and liver cirrhosis risk related to aflatoxin B1. ( 29937988 )
2018
25
MiR-27a as a predictor for the activation of hepatic stellate cells and hepatitis B virus-induced liver cirrhosis. ( 29416678 )
2018
26
Ratio of mean platelet volume to platelet count is a potential surrogate marker predicting liver cirrhosis. ( 29399281 )
2018
27
Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: a randomized controlled study. ( 29405667 )
2018
28
Liver Cirrhosis and/or Hepatocellular Carcinoma Occurring Late After the Fontan Procedurea88- A Nationwide Survey in Japan. ( 29445059 )
2018
29
Investigation on outcomes and bacterial distributions of liver cirrhosis patients with gram-negative bacterial bloodstream infection. ( 29423099 )
2018
30
Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: Efficacy and the risk of hemorrhagic complications. ( 29407630 )
2018
31
Large-volume paracentesis effects plasma disappearance rate of indo-cyanine green in critically ill patients with decompensated liver cirrhosis and intraabdominal hypertension. ( 29980962 )
2018
32
Transient portal vein thrombosis in liver cirrhosis. ( 29871683 )
2018
33
Assessment of prognostic performance of Albumin-Bilirubin, Child-Pugh, and Model for End-stage Liver Disease scores in patients with liver cirrhosis complicated with acute upper gastrointestinal bleeding. ( 29438135 )
2018
34
Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis. ( 29435187 )
2018
35
Gallbladder perforation in a patient with alcoholic liver cirrhosis and asymptomatic gallstones: A case report. ( 29718836 )
2018
36
The association between liver cirrhosis and fracture risk: a systematic review and meta-analysis. ( 29885255 )
2018
37
Effects of liver cirrhosis on portal vein embolization prior to right hepatectomy in patients with primary liver cancer. ( 29434832 )
2018
38
Circulating miR-21, miR-210 and miR-146a as potential biomarkers to differentiate acute tubular necrosis from hepatorenal syndrome in patients with liver cirrhosis: a pilot study. ( 29303765 )
2018
39
Discriminatory CT-textural features in splenic infiltration of lymphoma versus splenomegaly in liver cirrhosis versus normal spleens in controls and evaluation of their role for longitudinal lymphoma monitoring. ( 29857858 )
2018
40
Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. ( 29753054 )
2018
41
A study of serological markers and lipid profile in non-alcoholic liver cirrhosis patients. ( 29348089 )
2018
42
Surveillance for portal hypertension in the course of liver cirrhosis. ( 29904721 )
2018
43
Quantitative assessment of HLA-DQ gene polymorphisms with the development of hepatitis B virus infection, clearance, liver cirrhosis, and hepatocellular carcinoma. ( 29416599 )
2018
44
The prevalence and association of chronic kidney disease and diabetes in liver cirrhosis using different estimated glomerular filtration rate equation. ( 29416767 )
2018
45
Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. ( 29956689 )
2018
46
Immature platelet fraction and thrombopoietin in patients with liver cirrhosis: A cohort study. ( 29438423 )
2018
47
Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis. ( 29715144 )
2018
48
Low circulating chemerin levels correlate with hepatic dysfunction and increased mortality in decompensated liver cirrhosis. ( 29915268 )
2018
49
Risk of HBV reactivation in HBV+HCV coinfected patients with compensated liver cirrhosis treated with Ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin. ( 29397016 )
2018
50
Successful sequential liver and haematopoietic stem cell transplantation in a child with CD40 ligand deficiency and Cryptosporidium-induced liver cirrhosis. ( 29377874 )
2018
Sources

Variations for Liver Cirrhosis

About this section

Copy number variations for Liver Cirrhosis from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis
Sources

Expression for Liver Cirrhosis

About this section
Search GEO for disease gene expression data for Liver Cirrhosis.
Sources

Pathways for Liver Cirrhosis

About this section

Pathways related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
HIF-1 signaling pathway 37
11.5 EDN1 NPPA TF
2
Lung fibrosis 1
11.13 EDN1 HGF SERPINA1
3
Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.05 AFP ALB HGF SERPINA1
4
FOXA2 and FOXA3 transcription factor networks 1
10.78 AFP ALB F2
5
LncRNA-mediated mechanisms of therapeutic resistance 1
10.34 HOTAIR MEG3
Sources

GO Terms for Liver Cirrhosis

About this section

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.96 AFP ALB EDN1 F2 HGF NPPA
2 blood microparticle GO:0072562 9.62 ALB F2 SERPINC1 TF
3 platelet alpha granule lumen GO:0031093 9.58 ALB HGF SERPINA1
4 endoplasmic reticulum lumen GO:0005788 9.43 AFP ALB F2 SERPINA1 SERPINC1 TF
5 extracellular space GO:0005615 9.4 AFP ALB EDN1 F2 GPT HFE
6 HFE-transferrin receptor complex GO:1990712 9.37 HFE TF
7 basal part of cell GO:0045178 9.33 EDN1 HFE TF

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.77 AFP ALB SERPINA1 SERPINC1 TF
2 regulation of blood pressure GO:0008217 9.63 EDN1 NPPA REN
3 hemostasis GO:0007599 9.58 F2 SERPINA1 SERPINC1
4 response to muscle stretch GO:0035994 9.49 EDN1 NPPA
5 regulation of blood coagulation GO:0030193 9.48 F2 SERPINC1
6 cellular response to iron ion GO:0071281 9.43 HFE TF
7 acute-phase response GO:0006953 9.43 F2 HFE SERPINA1
8 response to ozone GO:0010193 9.32 CYP2E1 EDN1
9 platelet degranulation GO:0002576 9.26 ALB HGF SERPINA1 TF
10 cellular protein metabolic process GO:0044267 9.17 AFP ALB F2 NPPA SERPINA1 SERPINC1
11 regulation of iron ion import GO:1900390 9.16 HFE TF

Molecular functions related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 EDN1 F2 HFE NPPA REN
2 transferrin receptor binding GO:1990459 8.62 HFE TF
Sources

Sources for Liver Cirrhosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....